Posts

Common chemotherapy drugs don’t work like doctors thought, with big implications for drug discovery

Common chemotherapy drugs don’t work like doctors thoug...

Oct 26, 2023

A new study from the University of Wisconsin–Madison suggests that chemotherapy ...

A new NIR-PIT biomarker paves the way for targeted cancer treatments

A new NIR-PIT biomarker paves the way for targeted canc...

Oct 26, 2023

Researchers at Nagoya University in Japan and their collaborators have used a bi...

Merck eliminates two preclinical Kelun programs to reduce its ADC pipeline

Merck eliminates two preclinical Kelun programs to redu...

Oct 25, 2023

Merck & Co. has chosen to streamline its portfolio of antibody-drug conjugates (...

Roivant to Sell Gut Disease Drug to Roche in Deal Over $7B

Roivant to Sell Gut Disease Drug to Roche in Deal Over $7B

Oct 25, 2023

Approximately a year ago, pharmaceutical company Roivant Sciences established a ...

Roche invests $7 billion to compete with Merck in the bowel disease market

Roche invests $7 billion to compete with Merck in the b...

Oct 25, 2023

Roche has made a significant $7 billion investment to challenge Merck & Co in th...

Abemaciclib by Eli Lilly and Co for Neuroblastoma: Like...

Oct 25, 2023

Abemaciclib is under clinical development by Eli Lilly and Co and currently in P...

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for ...

Oct 25, 2023

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai)...

Alimta by Eli Lilly and Co for Triple-Negative Breast C...

Oct 25, 2023

Alimta is under clinical development by Eli Lilly and Co and currently in Phase ...

Trametinib dimethyl sulfoxide by Novartis for Relapsed ...

Oct 25, 2023

Trametinib dimethyl sulfoxide is under clinical development by Novartis and curr...

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for ...

Oct 25, 2023

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai)...

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for ...

Oct 25, 2023

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai)...

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for ...

Oct 25, 2023

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai)...

Surufatinib by Hutchison MediPharma for Neuroendocrine ...

Oct 25, 2023

Surufatinib is under clinical development by Hutchison MediPharma and currently ...

Ataluren by PTC Therapeutics for Duchenne Muscular Dyst...

Oct 25, 2023

Ataluren is under clinical development by PTC Therapeutics and currently in Phas...

SOF-10 by Chugai Pharmaceutical for Gastric Cancer: Lik...

Oct 25, 2023

SOF-10 is under clinical development by Chugai Pharmaceutical and currently in P...

STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax

STAT+: Pharmalittle: Pharma moves closer to a pricing d...

Oct 24, 2023

The pharmaceutical industry is close to a deal with the U.K. government over dru...